This study demonstrated that administration of afatinib was associated with a lower risk of treatment failure compared to that observed following the administration of erlotinib and gefitinib in patients with advanced NSCLC harboring EGFR mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.